0
Abstract: Slide Presentations |

HYDROFLUOROALKANE-134A BECLOMETHASONE DIPROPIONATE IS MORE EFFECTIVE THAN DOUBLE DOSE CHLOROFLUOROCARBON BECLOMETHASONE DIPROPIONATE FOR THE TREATMENT OF SEVERE ASTHMA FREE TO VIEW

Hideto Obata, MD*; Kenji Ikeda, MD
Author and Funding Information

Respiratory Division, Saiseikai, Shimonoseki, Japan


Chest


Chest. 2005;128(4_MeetingAbstracts):165S. doi:10.1378/chest.128.4_MeetingAbstracts.165S
Text Size: A A A
Published online

Abstract

PURPOSE:  The extent of lung deposition is known to be a major determinant of the therapeutic efficacy of inhaled corticosteroid. The lung deposition of extrafine aerosol of Hydrofluoroalkane-134a Beclomethasone Dipropionate (HFA-BDP) was found to be better compared with the suspension aerosol of chlorofluorocarbon beclomethasone dipropionate (CFC-BDP). The aim of this study is to evaluate pulmonary function in patients with severe asthma when CFC-BDP was changed over to HFA-BDP at half the daily dose.

METHODS:  This study enrolled patients (more than 20 years of age) with asthma who used high dose of CFC-BDP and whose symptom were stable with no history of exacerbation for the past year. Twenty-five adult patients with stable asthma and maintained on CFC-BDP, 800 to 2400 μg/day were recruited for this study. In addition, 36% of patients were given oral corticosteroid, 24% anti-leukotriene antagonist, 24% long β2 stimulant, 36% oral xanthine and 100% short acting β2 stimulant . Patients switched from their previous asthma treatment of CFC-BDP to HFA-BDP, at half the daily dose, while all other medications remained unchanged. Pulmonary function test was measured twice at 3 months interval during treatment with CFC-BDP and at3 months after switched over to HFA-BDP.

RESULTS:  Switching from CFC-BDP to HFA-BDP significantly improved pulmonary function including predicted FEV1 (from 71.7% to 81.2%), predicted MMF (from 47.0% to 61.0%), predicted V50 (from 39.1% to 50.3%) and predicted V25 (from 38.2% to 48.1%).

CONCLUSION:  These data suggest HFA-BDP may improve small airway of patients with severe asthma.

CLINICAL IMPLICATIONS:  Asthma therapy. Inhaled corticoteroid. HFA-BDP.

DISCLOSURE:  Hideto Obata, None.

Tuesday, November 1, 2005

10:30 AM - 12:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543